RT Journal Article
SR Electronic
T1 The counterpart congenital overgrowth syndromes Beckwith-Wiedemann Syndrome in human and large offspring syndrome in bovine involve alterations in DNA methylation, transcription, and chromatin configuration
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.14.23299981
DO 10.1101/2023.12.14.23299981
A1 Li, Yahan
A1 Xiao, Ping
A1 Boadu, Frimpong
A1 Goldkamp, Anna K.
A1 Nirgude, Snehal
A1 Cheng, Jianlin
A1 Hagen, Darren E.
A1 Kalish, Jennifer M.
A1 Rivera, Rocío Melissa
YR 2023
UL http://medrxiv.org/content/early/2023/12/16/2023.12.14.23299981.abstract
AB Beckwith-Wiedemann Syndrome (BWS, OMIM #130650) is a congenital epigenetic disorder in humans which affects approximately 1 in 10,340 children. The incidence is likely an underestimation as the condition is usually recognized based on observable phenotypes at birth. BWS children have up to a 28% risk of developing tumors and currently, only 80% of patients can be corroborated molecularly (epimutations/variants). It is unknown how the subtypes of this condition are molecularly similar/dissimilar globally, therefore there is a need to deeply characterize the syndrome at the molecular level. Here we characterize the methylome, transcriptome and chromatin configuration of 18 BWS individuals together with the animal model of the condition, the bovine large offspring syndrome (LOS). Sex specific comparisons are performed for a subset of the BWS patients and LOS. Given that this epigenetic overgrowth syndrome has been characterized as a loss-of-imprinting condition, parental allele-specific comparisons were performed using the bovine animal model. In general, the differentially methylated regions (DMRs) detected in BWS and LOS showed significant enrichment for CTCF binding sites. Altered chromosome compartments in BWS and LOS were positively correlated with gene expression changes, and the promoters of differentially expressed genes showed significant enrichment for DMRs, differential topologically associating domains, and differential A/B compartments in some comparisons of BWS subtypes and LOS. We show shared regions of dysregulation between BWS and LOS, including several HOX gene clusters, and also demonstrate that altered DNA methylation differs between the clinically epigenetically identified BWS patients and those identified as having DNA variants (i.e. CDKN1C microdeletion). Lastly, we highlight additional genes and genomic regions that have the potential to serve as targets for biomarker development to improve current molecular methodologies. In summary, our results suggest that genome-wide alternation of chromosome architecture, which is partially caused by DNA methylation changes, also contribute to the development of BWS and LOS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was partially funded by the United States Department of Agriculture Agriculture and Food Research Initiative (USDA AFRI), grant 20186701527598. This work was partially supported by National Cancer Institute [K08 CA193915], Alexs Lemonade Stand Foundation, a Damon Runyon Clinical Investigator Award provided by the Damon Runyon Cancer Research Foundation (105 19), the Lorenzo Turtle Sartini Jr. Endowed Chair in Beckwith-Wiedemann Syndrome Research, and the Victoria Fertitta Fund through the Lorenzo Turtle Sartini Jr. Endowed Chair in Beckwith-Wiedemann Syndrome Research (J.M.K.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Childrens Hospital of Philadelphia gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll the raw sequencing data for human samples, including whole genome bisulfite sequencing, total RNA sequencing, and HiC sequencing, are available in the database of Genotypes and Phenotypes (dbGaP) with accession number (phs001794.v1.p1). All the raw sequencing data for bovine samples, including whole genome bisulfite sequencing, total RNA sequencing, and HiC sequencing, are available in the Gene Expression Omnibus (GEO) database with accession number (pending).